Cubist Systematic Strategies, LLC Dexcom Inc Call Options Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$64.0 - $116.06 $819,200 - $1.49 Million	12,800 Added 17.8%	84,700 $5.68 Million
Q2 2024 Aug 14, 2024	SELL	$110.31 - $140.45 $3.7 Million - $4.71 Million	-33,500 Reduced 31.78%	71,900 $8.15 Million
Q1 2024 May 15, 2024	BUY	$114.22 - $140.1 $3.35 Million - $4.1 Million	29,300 Added 38.5%	105,400 $14.6 Million
Q4 2023 Feb 14, 2024	BUY	$75.49 - $124.16 $4.42 Million - $7.26 Million	58,500 Added 332.39%	76,100 $9.44 Million
Q3 2023 Nov 14, 2023	BUY	$86.06 - $137.93 $1.14 Million - $1.82 Million	13,200 Added 300.0%	17,600 $1.64 Million
Q2 2023 Aug 14, 2023	BUY	$112.47 - $130.98 $112,470 - $130,979	1,000 Added 29.41%	4,400 $565,000
Q1 2023 May 15, 2023	BUY	$104.0 - $122.92 $353,600 - $417,928	3,400 New	3,400 $395,000
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $274,860 - $339,048	-3,600 Reduced 69.23%	1,600 $129,000
Q2 2022 Aug 15, 2022	BUY	$67.99 - $132.89 $353,548 - $691,027	5,200 New	5,200 $388,000

1,015

349M

5.66M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $28.8B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.